DexCom, Inc. Share Price Berne S.E.
Equities
DC4
US2521311074
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
118.2 CHF | +7.35% | -.--% | -.--% |
Sales 2024 * | 4.33B 3.88B 362B | Sales 2025 * | 5.15B 4.61B 430B | Capitalization | 46.05B 41.24B 3,845B |
---|---|---|---|---|---|
Net income 2024 * | 728M 652M 60.79B | Net income 2025 * | 906M 811M 75.65B | EV / Sales 2024 * | 11 x |
Net Debt 2024 * | 1.43B 1.28B 120B | Net Debt 2025 * | 994M 890M 83.02B | EV / Sales 2025 * | 9.13 x |
P/E ratio 2024 * |
64.1
x | P/E ratio 2025 * |
52.4
x | Employees | 9,550 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.62% |
Latest transcript on DexCom, Inc.
1 day | +7.35% | ||
1 month | +7.35% | ||
3 months | +7.35% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Sayer
CEO | Chief Executive Officer | 66 | 01/07/01 |
Jereme Sylvain
DFI | Director of Finance/CFO | 44 | 01/18/01 |
Chief Tech/Sci/R&D Officer | 47 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nick Augustinos
BRD | Director/Board Member | 65 | 20/09/20 |
Mark Foletta
BRD | Director/Board Member | 63 | 19/14/19 |
Eric Topol
BRD | Director/Board Member | 69 | 09/09/09 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.26% | 187B | |
+2.05% | 110B | |
-1.31% | 69.54B | |
+14.65% | 46.37B | |
+7.97% | 42.54B | |
+18.60% | 30.72B | |
+16.92% | 25.62B | |
-6.87% | 23.32B | |
-10.63% | 22.92B |
- Stock Market
- Equities
- DXCM Stock
- DC4 Stock